ABUS Arbutus Biopharma Corp — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$4.25

Period return

-0.27 (-5.97%)

Volume

1.1M

2026-06-05O $4.34 H $4.36 L $4.21 C $4.25MA5 $4.34MA20 $4.38MA60 $4.37MA120 $4.41

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2025. 11. 15.LowBUY7 months ago
Chardan Capital: Buy
US analyst rating / recommendation change.
2025. 08. 11.LowBUY10 months ago
Chardan Capital: Buy
US analyst rating / recommendation change.
2025. 03. 28.LowBUYlast year
Chardan Capital: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $5.15 · 3 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
HQ: Warminster, PA, United States
Fiscal year end: —
Employees: 19
IPO date: —

2025. 01. 21.LowBUYlast year

HC Wainwright & Co.: Buy